The U. S. Food and Drug Administration (FDA) has announced a significant policy change to improve public trust by removing pharmaceutical company representatives from its advisory committees.
1. Change in Policy:
• FDA Commissioner Dr. Marty Makary stated the need to eliminate industry influence to restore public confidence in the FDA's decisions.
• The decision affects the 32 advisory committees that influence decisions on vaccines, medical devices, and pharmaceuticals.
2. Reason for Change:
• There has been a historical concern about the undue influence of corporate interests on the FDA.
• Critics claim that even non-voting industry members can sway opinions of voting members, leading to conflicts between pharmaceutical profits and public health.
3. Focus on Patients:
• The FDA aims to strengthen the roles of patients and caregivers in the regulatory process.
• Industry employees can still attend meetings as part of the public but will not be official members.
4. Examples of Negative Influence:
• Cases like the approval of the pain reliever Vioxx, which was linked to severe health risks, illustrate the dangers of industry pressure.
• The opioid crisis, driven by aggressive marketing of dangerous drugs, highlights the consequences of industry influence.
5. Call for Integrity:
• Commissioner Makary emphasizes the urgency of restoring integrity to FDA processes and ensuring that decisions are based on sound science rather than corporate interests.
The FDA's decision to remove pharmaceutical industry representatives from its advisory committees is a crucial step toward rebuilding public trust and ensuring that healthcare and regulatory decisions prioritize the well-being of the public over corporate agendas.
https://www.naturalnews.com/2025-04-22-fda-to-remove-pharma-reps-from-advisory-panels.html
No comments:
Post a Comment